Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SLC16A1 | P53985 | 3/20 | 0.36 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.36 |
| ▸ | PDE1A | P54750 | 1/20 | 0.35 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.35 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.35 |
| ▸ | CMA1 | P23946 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5410898 | 0.90 | CTSL (0.34) | LMNASLC16A1SHMT2PDE1APDE1B | |
| SCHEMBL5406059 | 0.86 | SLC16A1 (0.39) | LMNASLC16A1PDE1APDE1BPDE1C | |
| Hydrochloric Acid SCHEMBL5402776 | 0.86 | SLC16A1 (0.38) | LMNASLC16A1PDE1APDE1BPDE1C | |
| SCHEMBL5405716 | 0.85 | TP53 (0.44) | LMNASLC16A1PDE1APDE1BPDE1C | |
| SCHEMBL5402570 | 0.85 | SLC16A1 (0.36) | LMNASLC16A1SHMT2PDE1APDE1B | |
| SCHEMBL5398848 | 0.82 | PDE1A (0.37) | SLC16A1PDE1APDE1BPDE1C | |
| SCHEMBL5411081 | 0.81 | SMN1; SMN2 (0.41) | SLC16A1PDE1APDE1BPDE1CCMA1 | |
| SCHEMBL5400117 | 0.80 | CMA1 (0.37) | SLC16A1PDE1APDE1BPDE1CCMA1 | |
| SCHEMBL5404342 | 0.80 | PDE1A (0.38) | SLC16A1PDE1APDE1BPDE1CCMA1 | |
| SCHEMBL5395357 | 0.80 | PDE5A (0.39) | SLC16A1PDE1APDE1BPDE1CCMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285558-B2 | Pyrazolo[3,4-d]pyrimidines inhibiting H. pylori infections | ASTRAZENECA AB (SE) | 2007-10-23 | — | — | US | disclosed |
| US-7285558-B2 | Pyrazolo[3,4-d]pyrimidines inhibiting H. pylori infections | ASTRAZENECA AB (SE) | 2007-10-23 | — | — | US | disclosed |
| US-7285558-B2 | Pyrazolo[3,4-d]pyrimidines inhibiting H. pylori infections | ASTRAZENECA AB (SE) | 2007-10-23 | — | — | US | disclosed |
| US-20040254183-A1 | Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections | ASTRAZENECA AB (SE) | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254183-A1 | Pyrazolo[3,4-d]pyrimidines inhibiting h. pylori infections | DPYD, HPGDS, PGC | LMNA 4673/4885SLC16A1 4140/4885SHMT2 3524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.